RICHMOND, Calif., June 20, 2017 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) announced today that it has
commenced an underwritten public offering of shares of its common
stock. All of the shares in the offering are to be sold by
Sangamo. Sangamo intends to grant the underwriters a 30 day option
to purchase up to 15% of the number of shares of common stock to be
sold in the offering. Sangamo intends to use the proceeds from this
offering for working capital and other general corporate purposes,
including support for the continuing research and development of
its genomic therapy product candidates and research programs,
clinical trials, commercialization activities, business development
activities and, if opportunities arise, acquisitions of businesses,
products, technologies or licenses that are complementary to
Sangamo's business.
Cowen and Company, LLC and Wells Fargo Securities, LLC are
acting as joint book-running managers for the offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above
was filed with the Securities and Exchange Commission (the "SEC")
and is effective. A preliminary prospectus supplement
relating to the offering has been filed with the SEC. Copies
of the preliminary prospectus supplement and accompanying
prospectus may be obtained, when available, from the offices of
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at (866) 803-9204, or from Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, New York 10152,
or by telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale is not
permitted. The offering is subject to market and other conditions
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
About Sangamo
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic therapies that transform
patients' lives using the company's industry leading platform
technologies in genome editing, gene therapy, gene regulation and
cell therapy.
Forward Looking Statements
This press release may contain forward-looking statements
based on Sangamo's current expectations. These forward-looking
statements include, without limitation, the proposed public
offering of shares of common stock and use of proceeds from the
proposed offering. Actual results may differ materially from these
forward-looking statements due to a number of factors, including
uncertainties relating to the completion of the public offering on
the anticipated terms or at all, market conditions and the
satisfaction of customary closing conditions related to the
proposed offering. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this
press release. Additional risks and uncertainties relating to
Sangamo and its business can be found under the heading "Risk
Factors" in Sangamo's Registration Statement on Form S-3, as
amended, initially filed with the SEC on May
26, 2017. Sangamo assumes no obligation to update the
forward-looking information contained in this press
release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-proposed-public-offering-of-common-stock-300476858.html
SOURCE Sangamo Therapeutics, Inc.